

# Valentina Fanotto

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6924661/valentina-fanotto-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

37  
papers

705  
citations

15  
h-index

26  
g-index

54  
ext. papers

896  
ext. citations

4.1  
avg, IF

3.55  
L-index

#	Paper	IF	Citations
37	A rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring. <i>PLoS ONE</i> , <b>2021</b> , 16, e0259137	3.7	0
36	LDH as prognostic factor in second line treatment for advanced gastric cancer: The LINE study.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e16102-e16102	2.2	0
35	Prognostic role of visceral fat for overall survival in metastatic colorectal cancer: A pilot study. <i>Clinical Nutrition</i> , <b>2021</b> , 40, 286-294	5.9	8
34	The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer. <i>Oncologist</i> , <b>2020</b> , 25, 661-668	5.7	6
33	Epstein-Barr virus BART microRNAs in EBV- associated Hodgkin lymphoma and gastric cancer. <i>Infectious Agents and Cancer</i> , <b>2020</b> , 15, 42	3.5	10
32	Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study. <i>Future Oncology</i> , <b>2020</b> , 16, 2059-2073	3.6	1
31	Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis. <i>Scientific Reports</i> , <b>2020</b> , 10, 7010	4.9	8
30	Gastric cancer: Translating novels concepts into clinical practice. <i>Cancer Treatment Reviews</i> , <b>2019</b> , 79, 101889	14.4	39
29	Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker. <i>Cancers</i> , <b>2019</b> , 11,	6.6	17
28	New Agents in the Treatment of Advanced Gastric Cancer: Targeted Therapy and Immunotherapy. <i>Current Clinical Pathology</i> , <b>2019</b> , 121-132	0.1	
27	Serum Biomarkers in Gastric Cancer. <i>Current Clinical Pathology</i> , <b>2019</b> , 107-117	0.1	
26	The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , <b>2019</b> , 10, 368-377	10.3	36
25	Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. <i>Journal of Geriatric Oncology</i> , <b>2019</b> , 10, 591-597	3.6	4
24	Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation. <i>Cancer Treatment Reviews</i> , <b>2019</b> , 72, 7-14	14.4	12
23	Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey. <i>Breast</i> , <b>2018</b> , 40, 45-52	3.6	4
22	Determinants of Last-line Treatment in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , <b>2018</b> , 18, 205-213	3.5	7
21	Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram. <i>Oncology</i> , <b>2018</b> , 95, 344-352	3.6	9

20	Prognostic role of alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) in metastatic breast cancer (MBC) patients: First clues for cost-effective biomarkers.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e13079-e13079	2.2	2
19	Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle. <i>Expert Opinion on Biological Therapy</i> , <b>2017</b> , 17, 365-374	5.4	23
18	Sarcopenia in gastric cancer: when the loss costs too much. <i>Gastric Cancer</i> , <b>2017</b> , 20, 563-572	7.6	33
17	Immunotherapy for colorectal cancer: where are we heading?. <i>Expert Opinion on Biological Therapy</i> , <b>2017</b> , 17, 709-721	5.4	71
16	Immunotherapy for gastric cancers: emerging role and future perspectives. <i>Expert Review of Clinical Pharmacology</i> , <b>2017</b> , 10, 609-619	3.8	26
15	Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. <i>Gastric Cancer</i> , <b>2017</b> , 20, 825-833	7.6	24
14	Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough. <i>Future Oncology</i> , <b>2017</b> , 13, 2265-2275	3.6	8
13	Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. <i>Oncologist</i> , <b>2017</b> , 22, 1463-1469	5.7	17
12	New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury. <i>Frontiers in Pharmacology</i> , <b>2017</b> , 8, 354	5.6	96
11	Molecular classifications of gastric cancers: Novel insights and possible future applications. <i>World Journal of Gastrointestinal Oncology</i> , <b>2017</b> , 9, 194-208	3.4	38
10	Determinants of adjuvant chemotherapy use in small luminal-like breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e12010-e12010	2.2	
9	Preliminary results from CAMEO-PRO study: Complementary and alternative medicine in oncology Physicians inform oncological patients.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e21632-e21632	2.2	
8	Prognostic factors in 868 advanced gastric cancer patients exposed to second-line therapy.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e15553-e15553	2.2	
7	HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives. <i>Oncotarget</i> , <b>2016</b> , 7, 69060-69074	3.3	21
6	Do platinum salts fit all triple negative breast cancers?. <i>Cancer Treatment Reviews</i> , <b>2016</b> , 48, 34-41	14.4	38
5	FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The phase II randomized MOMA trial. <i>Annals of Oncology</i> , <b>2016</b> , 27, vi560	10.3	4
4	Skeletal metastases from breast cancer: pathogenesis of bone tropism and treatment strategy. <i>Clinical and Experimental Metastasis</i> , <b>2015</b> , 32, 819-33	4.7	24
3	Pattern of metastasis and outcome in patients with breast cancer. <i>Clinical and Experimental Metastasis</i> , <b>2015</b> , 32, 125-33	4.7	101

- 2 Treatment during the last month of life in advanced cancer patients.. *Journal of Clinical Oncology*, **2015**, 33, e17649-e17649 2.2
- 1 Pattern of metastatic spread and prognosis of breast cancer biologic subtypes.. *Journal of Clinical Oncology*, **2014**, 32, e12532-e12532 2.2 6